EX VIVO CULTURE OF ATHEROMA-DERIVED TISSUE AND CELLS. Ex vivo atheroma cultures were set up as previously described (10 C1  C2  C3  C4  C5  C6  C7  C8  C9  C10  P1  P2  P3  P4  P5  P6  P7  P8  P9  P10   NLRP1  NLRP2  NLRP3  NLRP4  NLRP5  NLRP6  NLRP7  NLRP8  NLRP9  NLRP10  NLRP11  NLRP12  NLRP13  NLRP14  NLRC3  NLRC4  NLRC5  NAIP  AIM2  CASP1  CASP4  CASP5  CASP8  CASP12  MEFV  ASC  IL1- CARD domain-containing protein (NLRC) 4 activator Salmonella typhimurium (S. typh) (10 mmol/l), or absent in melanoma 2 activator poly(deoxyadenylic-deoxythymidylic acid) (poly dA dT) (10 mg/ml). The concentration of IL-1b in the supernatant was quantified using enzyme-linked immunosorbent assay (ELISA). Data are shown as mean AE SEM; n ¼ 3 to 7. ns, not significant (Mann-Whitney U test). (G,H)
Release of IL-1 cytokines from atherosclerotic plaque samples upon lipopolysaccharide (LPS) challenge (100 ng/ml for 24 h). IL-1a (n ¼ 16) and IL-1b (n ¼ 24) concentrations in the supernatant were measured by ELISA. P values are based on Mann-Whitney U test. Ctrl ¼ control;
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by either computed tomography, ultrasound, and/or magnetic resonance imaging, severe calcification, intraplaque hemorrhage, or ulceration, alone or combined, was reported in 15 (72%) cases, herein referred to as complex plaques ( Figure 4A ). The presence of both IL-1a and IL-1b was recently observed in human atherosclerotic plaques (23) .
Taking the advantage of ex vivo culture of The present study lends support to biological plaque activity-directed treatment efforts and the testing thereof in future clinical trials.
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